Dare Bioscience Inc DARE.OQ DARE.O is expected to show a rise in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The San Diego California-based company is expected to report a 757.6% increase in revenue to $188.67 thousand from $22 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00, about 84.8% above its last closing price of $1.97
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.58 | -0.58 | -0.50 | Beat | 13.8 |
Dec. 31 2025 | -0.53 | -0.65 | Missed | -21.9 | |
Sep. 30 2024 | -0.76 | -0.73 | -0.55 | Beat | 25 |
Jun. 30 2024 | -0.65 | 0.00 | 1.52 | Beat | |
Mar. 31 2024 | -0.72 | -0.72 | -0.84 | Missed | -16.7 |
Dec. 31 2023 | -1.60 | -1.18 | -0.72 | Beat | 38.8 |
Sep. 30 2023 | -1.16 | -1.18 | -1.08 | Beat | 8.2 |
Jun. 30 2023 | -1.21 | -1.18 | -1.20 | Missed | -1.7 |
This summary was machine generated August 12 at 20:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)